1. Home
  2. EDF vs BNR Comparison

EDF vs BNR Comparison

Compare EDF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

EDF

Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

N/A

Current Price

$4.41

Market Cap

166.0M

Sector

Finance

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$10.40

Market Cap

169.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDF
BNR
Founded
N/A
2014
Country
United States
China
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.0M
169.9M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
EDF
BNR
Price
$4.41
$10.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 181.2K
19.4K
Earning Date
01-01-0001
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$101.46
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.16
$6.79
52 Week High
$5.67
$41.72

Technical Indicators

Market Signals
Indicator
EDF
BNR
Relative Strength Index (RSI) 39.34 35.76
Support Level N/A $8.91
Resistance Level $5.41 $10.72
Average True Range (ATR) 0.12 1.67
MACD 0.02 -0.41
Stochastic Oscillator 45.63 6.98

Price Performance

Historical Comparison
EDF
BNR

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: